Shuttle Pharmaceuticals Holdings IncNASDAQ:SHPHNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8710
- TODAY'S CHANGE (%)-0.0110 (-1.2472%)
- Bid / Lots0.8700/ 3
- Ask / Lots0.8940/ 20
- Open / Previous Close0.8710 / 0.8820
- Day Range
- 52 Week Range
- Volume83,184
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SHPH |
|---|---|---|
| 09:32 ET | 1937 | 0.871 |
| 09:33 ET | 112 | 0.8711 |
| 09:46 ET | 250 | 0.87101 |
| 10:06 ET | 100 | 0.88 |
| 10:08 ET | 999 | 0.871 |
| 10:15 ET | 100 | 0.88 |
| 10:36 ET | 2227 | 0.8536 |
| 10:49 ET | 1000 | 0.869101 |
| 11:00 ET | 3000 | 0.8879 |
| 11:07 ET | 100 | 0.8691 |
| 11:12 ET | 300 | 0.8857 |
| 11:38 ET | 1000 | 0.891 |
| 11:48 ET | 1000 | 0.880501 |
| 12:10 ET | 200 | 0.8776 |
| 12:26 ET | 300 | 0.875 |
| 01:02 ET | 1000 | 0.880051 |
| 01:04 ET | 2202 | 0.8805 |
| 01:06 ET | 1000 | 0.8805 |
| 01:09 ET | 1477 | 0.880051 |
| 01:15 ET | 600 | 0.8883 |
| 01:18 ET | 1250 | 0.8836 |
| 01:31 ET | 222 | 0.8836 |
| 01:33 ET | 6885 | 0.8868 |
| 01:36 ET | 112 | 0.89 |
| 01:40 ET | 1100 | 0.8836 |
| 01:42 ET | 1800 | 0.8868 |
| 01:47 ET | 308 | 0.8867 |
| 02:09 ET | 300 | 0.8837 |
| 02:14 ET | 200 | 0.8836 |
| 02:18 ET | 1000 | 0.8837 |
| 02:43 ET | 876 | 0.8836 |
| 02:52 ET | 100 | 0.8836 |
| 03:01 ET | 400 | 0.8838 |
| 03:03 ET | 500 | 0.8837 |
| 03:06 ET | 2400 | 0.8868 |
| 03:08 ET | 332 | 0.89 |
| 03:10 ET | 400 | 0.8836 |
| 03:17 ET | 900 | 0.8837 |
| 03:19 ET | 1440 | 0.8869 |
| 03:30 ET | 200 | 0.888 |
| 03:32 ET | 3400 | 0.8875 |
| 03:35 ET | 2100 | 0.88487 |
| 03:37 ET | 4864 | 0.891 |
| 03:39 ET | 4315 | 0.9061 |
| 03:44 ET | 2700 | 0.895076 |
| 03:55 ET | 200 | 0.89 |
| 03:57 ET | 534 | 0.8786 |
| 04:00 ET | 22793 | 0.871 |
Nov 13, 2024
Shuttle Pharma Provides Third Quarter 2024 Corporate Update, from 5:00PM ET on Wednesday Nov 13, 2024 by Dow Jones
5:00PM ET on Wednesday Nov 13, 2024 by Dow Jones
Oct 29, 2024
*DJ Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules, from 9:15PM ET on Tuesday Oct 29, 2024 by Dow Jones
9:15PM ET on Tuesday Oct 29, 2024 by Dow JonesShuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules, from 9:05PM ET on Tuesday Oct 29, 2024 by Dow Jones
9:05PM ET on Tuesday Oct 29, 2024 by Dow JonesShuttle Pharma Pays Off Senior Secured Convertible Note, from 4:05PM ET on Tuesday Oct 29, 2024 by Dow Jones
4:05PM ET on Tuesday Oct 29, 2024 by Dow JonesShuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma, from 9:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
9:00AM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Shuttle Pharmaceuticals Holdings Inc | 2.9M | -0.1x | --- |
Genprex Inc | 3.0M | -0.1x | --- |
Bone Biologics Corp | 3.0M | -0.2x | --- |
Theriva Biologics Inc | 2.9M | -0.1x | --- |
Actavia Life Sciences Inc | 3.1M | -7.5x | --- |
Revelation Biosciences Inc | 2.8M | 0.0x | --- |
Company Information
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company. The Company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). It is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.
Contact Information
- Headquarters
- 401 Professional Drive, Suite 260GAITHERSBURG, MD, United States 20879
- Phone
- 240-403-4212
- Fax
- 845-818-3588
Executives
- Chairman of the Board, Chief Executive Officer
- Anatoly Dritschilo
- President, Chief Operating Officer
- Peter Dritschilo
- Chief Financial Officer
- Timothy Lorber
- Chief Scientific Officer - Biology
- Mira Jung
- Chief Medical Officer, Chief Clinical Officer
- Tyvin Rich
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 3.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-10.29 |
Book Value | $2.02 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
